You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Pembrolizumab; Lenvatinib; Advanced Renal Cell Carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Carcinoma, Renal Cell Trial in China (Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab)

Recruiting
  • Carcinoma, Renal Cell
  • Pembrolizumab
  • +3 more
  • Beijing, Beijing, China
  • +16 more
Jun 2, 2023

Advanced Solid Tumor, Metastatic Solid Tumor, NSCLC Trial in Suwon-si, Daejeon, Seoul (GI-101, Pembrolizumab, Lenvatinib)

Recruiting
  • Advanced Solid Tumor
  • +7 more
  • Suwon-si, Kyeonggi-do, Korea, Republic of
  • +3 more
Apr 19, 2022

Renal Cell Carcinoma Trial (Neoadjuvant Lenvatinib, Neoadjuvant Pembrolizumab, Radical nephrectomy, IVC thrombectomy,

Not yet recruiting
  • Renal Cell Carcinoma
  • Neoadjuvant Lenvatinib
  • +3 more
  • (no location specified)
Dec 23, 2022

Renal Cell Carcinoma Trial in Philadelphia (Pembrolizumab infusion, Lenvatinib tablet)

Not yet recruiting
  • Renal Cell Carcinoma
  • Pembrolizumab infusion
  • Lenvatinib tablet
  • Philadelphia, Pennsylvania
    Abramson Cancer Center at University of Pennsylvania
Feb 8, 2023

Advanced Kidney Cancer Trial in Tianjin (Pembrolizumab plus Lenvatinib)

Recruiting
  • Advanced Kidney Cancer
  • Pembrolizumab plus Lenvatinib
  • Tianjin, Tianjin, China
    Changyi Quan
Aug 4, 2022

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Advanced Biliary Tract Carcinoma Trial in Shanghai (Pembrolizumab Injection [Keytruda], Lenvatinib Mesylate)

Recruiting
  • Advanced Biliary Tract Carcinoma
  • Pembrolizumab Injection [Keytruda]
  • Lenvatinib Mesylate
  • Shanghai, Shanghai, China
  • +1 more
Jul 19, 2022

Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung

Not yet recruiting
  • Advanced Non-squamous Non-small-cell Lung Cancer
  • +2 more
  • Beijing, Beijing, China
    Peking University First Hospital Ethics Committee
Sep 10, 2023

Fumarate Hydratase Deficient Renal Cell Carcinoma Trial (Tislelizumab, Lenvatinib)

Not yet recruiting
  • Fumarate Hydratase Deficient Renal Cell Carcinoma
  • (no location specified)
May 18, 2023

Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin, Trabecular Carcinoma of the Skin Trial in Tampa (Lenvatinib Oral

Recruiting
  • Merkel Cell Carcinoma
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
Dec 30, 2022

Tumors, Kidney Tumors, Urologic Tumors Trial in Nanjing (Toripalimab, Axitinib, Lenvatinib)

Recruiting
  • Neoplasms
  • +12 more
  • Nanjing, Jiangsu, China
    Jinling Hospital, Affiliated Hospital of Medical School, Nanjing
Oct 28, 2023

Renal Cell Carcinoma Trial in Guangzhou (Pucotenlimab Combined With Lenvatinib)

Not yet recruiting
  • Renal Cell Carcinoma
  • Pucotenlimab Combined With Lenvatinib
  • Guangzhou, Other (Non U.s.), China
    Sun Yat-sen University Cancer Center
Nov 10, 2023

Ovarian Clear Cell Carcinoma, Gynecologic Cancer Trial in Boston (Lenvatinib, Pembrolizumab)

Recruiting
  • Ovarian Clear Cell Carcinoma
  • Gynecologic Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Oct 13, 2022

Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer Trial in Tampa (Pembrolizumab, Lenvatinib)

Active, not recruiting
  • Neuroendocrine Tumors
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jan 24, 2023

Melanoma, Renal Cell Carcinoma, Brain Metastases Trial in New Haven (Pembrolizumab, Lenvatinib)

Recruiting
  • Melanoma
  • +6 more
  • New Haven, Connecticut
    Yale University
Feb 18, 2022

Renal Cell Carcinoma Trial in Beijing, Seoul (RO7247669, Tiragolumab, Pembrolizumab)

Recruiting
  • Renal Cell Carcinoma
  • Beijing, China
  • +1 more
Mar 28, 2023

Renal Cell Carcinoma Trial (Pembrolizumab)

Completed
Has Results
  • Renal Cell Carcinoma
  • Pembrolizumab
  • (no location specified)
Aug 17, 2022

Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic Trial in Iowa City (Selenomethionine (SLM),

Recruiting
  • Clear Cell Renal Cell Carcinoma
  • Clear Cell Renal Cell Carcinoma Metastatic
  • Selenomethionine (SLM)
  • +2 more
  • Iowa City, Iowa
    University of Iowa Hospitals & Clinics
Sep 19, 2022

Head and Neck Squamous Cell Carcinoma Trial in Germany (Pembrolizumab, Lenvatinib)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Augsburg, BY, Germany
  • +7 more
Jun 20, 2022

Untreated Advanced or Recurrent Thymic Carcinomas Trial in Chuo (MK-3475, Lenvatinib, Carboplatin)

Not yet recruiting
  • Untreated Advanced or Recurrent Thymic Carcinomas
  • Chuo, Tokyo, Japan
    National Cancer Center Hospital
Apr 16, 2023

Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)

Not yet recruiting
  • Solid Tumor
  • +2 more
  • favezelimab/pembrolizumab
  • +2 more
  • (no location specified)
Sep 7, 2023

Clear-cell Metastatic Renal Cell Carcinoma Trial in Guangzhou (Drug: Pembrolizumab)

Not yet recruiting
  • Clear-cell Metastatic Renal Cell Carcinoma
  • Drug: Pembrolizumab
  • Guangzhou, Guangdong, China
  • +1 more
Oct 7, 2022

Cadonilimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy Trial in Guangzhou (Cadonilimab Combined With Lenvatinib)

Recruiting
  • Cadonilimab
  • +2 more
  • Cadonilimab Combined With Lenvatinib
  • Guangzhou, Other (Non U.s.), China
    Sun Yat-sen University Cancer Center
Nov 16, 2023

Advanced Renal Cell Carcinoma Trial (QL1706 Plus Lenvatinib)

Not yet recruiting
  • Advanced Renal Cell Carcinoma
  • QL1706 Plus Lenvatinib
  • (no location specified)
Feb 21, 2022

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guanzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 24, 2023